Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

MDM2 inhibition with navtemadlin in myelofibrosis: from BOREAS to POIESIS

Pankit Vachhani, MD, University of Alabama at Birmingham, Birmingham, AL, presents on navtemadlin, an MDM2 inhibitor that restores p53 activity in patients with myelofibrosis. Dr Vachhani highlights spleen and symptom outcomes from the Phase III BOREAS trial (NCT03662126) of navtemadlin versus best available therapy and the Phase Ib/II KRT-232-109 study (NCT04485260) of navtemadlin added to ruxolitinib. He also outlines the design of the ongoing Phase III POIESIS trial (NCT06479135). This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.